(Reuters) – Pfizer Inc’s experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.
https://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.png00Reuters: Health Newshttps://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.pngReuters: Health News2018-03-29 20:33:312018-03-29 22:42:25Pfizer’s rare heart disease drug succeeds in late-stage study